Structure Therapeutics Stock (NASDAQ:GPCR)
Previous Close
$41.14
52W Range
$26.61 - $72.16
50D Avg
$39.60
200D Avg
$40.28
Market Cap
$2.27B
Avg Vol (3M)
$672.11K
Beta
-5.13
Div Yield
-
GPCR Company Profile
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| MORF | Morphic Holding, Inc. |
| MREO | Mereo BioPharma Group plc |
| BMEA | Biomea Fusion, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| IRON | Disc Medicine, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ELDN | Eledon Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |